PLSE vs. IRTC, BLCO, TMDX, SLNO, NVST, PRCT, LIVN, ENOV, NVCR, and WRBY
Should you be buying Pulse Biosciences stock or one of its competitors? The main competitors of Pulse Biosciences include iRhythm Technologies (IRTC), Bausch + Lomb (BLCO), TransMedics Group (TMDX), Soleno Therapeutics (SLNO), Envista (NVST), PROCEPT BioRobotics (PRCT), LivaNova (LIVN), Enovis (ENOV), NovoCure (NVCR), and Warby Parker (WRBY). These companies are all part of the "medical equipment" industry.
Pulse Biosciences vs.
Pulse Biosciences (NASDAQ:PLSE) and iRhythm Technologies (NASDAQ:IRTC) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, community ranking, analyst recommendations, risk, profitability and earnings.
iRhythm Technologies has a consensus price target of $128.55, indicating a potential downside of 8.10%. Given iRhythm Technologies' stronger consensus rating and higher probable upside, analysts plainly believe iRhythm Technologies is more favorable than Pulse Biosciences.
Pulse Biosciences has a beta of 1.6, meaning that its stock price is 60% more volatile than the S&P 500. Comparatively, iRhythm Technologies has a beta of 1.34, meaning that its stock price is 34% more volatile than the S&P 500.
In the previous week, iRhythm Technologies had 8 more articles in the media than Pulse Biosciences. MarketBeat recorded 10 mentions for iRhythm Technologies and 2 mentions for Pulse Biosciences. iRhythm Technologies' average media sentiment score of 1.41 beat Pulse Biosciences' score of 1.10 indicating that iRhythm Technologies is being referred to more favorably in the news media.
Pulse Biosciences has higher earnings, but lower revenue than iRhythm Technologies.
76.9% of Pulse Biosciences shares are owned by institutional investors. 71.5% of Pulse Biosciences shares are owned by insiders. Comparatively, 1.1% of iRhythm Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Pulse Biosciences has a net margin of 0.00% compared to iRhythm Technologies' net margin of -19.14%. Pulse Biosciences' return on equity of -96.89% beat iRhythm Technologies' return on equity.
iRhythm Technologies received 166 more outperform votes than Pulse Biosciences when rated by MarketBeat users. Likewise, 66.19% of users gave iRhythm Technologies an outperform vote while only 63.50% of users gave Pulse Biosciences an outperform vote.
Summary
iRhythm Technologies beats Pulse Biosciences on 9 of the 16 factors compared between the two stocks.
Get Pulse Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for PLSE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pulse Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:PLSE) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy PLSE Stock Free PLSE Stock Alerts